| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Polman), VU Medical Center, Amsterdam, the Netherlands; Department of Neurology (Dr. Kappos), University Hospitals Basel, Switzerland; Department of Statistics (Dr. Petkau, R. White), University of British Columbia, Vancouver, Canada; Schering AG (Dr. Dahlke and K. Beckmann), Berlin, Germany; Department of Neurology (Dr. Pozzilli), University of Rome "La Sapienza," Italy; and Department of Neurology (Drs. Thompson and Miller), National Hospital, London, UK.
Address correspondence and reprint requests to Dr. C. Polman, Department of Neurology, VU Medical Centre, de Boelelaan 1117, NL-1007 MB Amsterdam, the Netherlands; e-mail: ch.polman{at}vumc.nl
Objective: To investigate the relationship between neutralizing antibodies (NAB) and disease progression, relapses, and MR measures of MS.
Methods: Sequential serum samples from all 718 patients of the European Study Group in Interferon ß-1b in Secondary Progressive MS were analyzed to investigate relations between NAB and disease progression, relapses, and MR measures.
Results: This study showed no attenuating effect of NAB development on progression in disability. The effects of NAB on relapse rate showed substantial variation, depending on the statistical approach and definition of positivity, though analyses comparing low- and high-NAB+ periods with NAB- periods suggested a titer-related effect. MR T2 lesion volume changes from baseline were significantly higher for NAB+ patients but remained lower than for placebo patients. A substantial proportion of NAB+ patients became NAB-. No untoward effect of NAB development on safety was observed.
Conclusion: These results support the conclusion that even though high NAB titers appear to have impact on treatment efficacy with respect to relapses, treatment decisions should be based primarily on clinical grounds.
This article has been cited by other articles:
|
|
 |
|
  P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Sorensen, A. Bertolotto, and D. S. Goodin Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, October 9, 2007; 69(15): 1552 - 1553. [Full Text] [PDF]
|
|
|
|
|
|
P. Sorensen, N. Koch-Henriksen, and K. Bendtzen Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621. [Abstract] [PDF]
|
|
|
|
|
|
M. Cantillon and I. Antonijevic Clinical relevance of anti-drug antibodies with interferon beta-1b therapy in multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(1_suppl): 21 - 27. [Abstract] [PDF]
|
|
|
|
|
|
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
A.T. Reder Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 27, 2007; 68(13): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746. [Abstract] [PDF]
|
|
|
|
|
|
M H Gottesman and S Friedman-Urevich Interferon beta-1b (Betaseron(R)/Betaferon(R)) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS) Multiple Sclerosis, June 1, 2006; 12(3): 271 - 280. [Abstract] [PDF]
|
|
|
|
|
|
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al. Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study Neurology, July 12, 2005; 65(1): 40 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saida, K. Tashiro, Y. Itoyama, T. Sato, Y. Ohashi, Z. Zhao, and the Interferon Beta-1b Multiple Sclerosis Study Gr Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study Neurology, February 22, 2005; 64(4): 621 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The North American Study Group on Interferon beta- Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study Neurology, November 23, 2004; 63(10): 1788 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis Neurology, June 8, 2004; 62(11): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rudge Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis? Multiple Sclerosis, April 1, 2004; 10(2): 123 - 125. [PDF]
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Petkau Statistical approaches to assessing the effects of neutralizing antibodies: IFN{beta}-1b in the pivotal trial of relapsing-remitting multiple sclerosis Neurology, November 11, 2003; 61(90095): S35 - 37. [Abstract] [Full Text]
|
|
|
|
|
|
G. Giovannoni, C. H. Polman, J. Petkau, R. White, A. Thompson, D. H. Miller, F. Dahlke, and L. Kappos Neutralizing antibodies during treatment of secondary progressive MS with interferon {beta}-1b Neurology, October 14, 2003; 61(7): 1025 - 1025. [Full Text] [PDF]
|
|
|
|
 |
|
 C H Polman, L Kappos, J Petkau, and A Thompson Neutralising antibodies to interferon {beta} during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1162 - 1162. [Full Text] [PDF]
|
|
|
|
|
|
C Ortenzi, G Giovannoni, F Deisenhammer, and F E Munschauer Neutralising antibodies to interferon {beta} J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1162 - 1163. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
